CAD and Guillain-Barre syndrome: Pregnant women and newborn (NCT01446289) The aforementioned phase I trial using III-TT vaccine in pregnant women reported that 19 of 20 recipients had 4-fold increases in III CPS-specific IgG after vaccination relative to pre-vaccination levels, infant cord levels were approximately 70% of maternal values at delivery, and opsonophagocytic killing measured in sera of infants born to vaccine- but not placebo-recipients persisted until 2 months of age, suggesting the potential to protect against both early- and late-onset GBS infant disease175.